Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234183 | 0.78 | FDPS (0.50) | FDPSBLMTDP1LMNABTN3A1 | |
| SCHEMBL14439051 | 0.74 | FDPS (0.45) | FDPSBLMTDP1PGK1PGK2 | |
| SCHEMBL6901146 | 0.74 | — | — | |
| SCHEMBL28623681 | 0.72 | LMNA (0.57) | FDPSBLMTDP1PGK1PGK2 | |
| SCHEMBL10128514 | 0.70 | TSHR (0.42) | TDP1PGK1PGK2GRM4 | |
| Pyrophosphoric Acid SCHEMBL28750281 | 0.70 | FDPS (0.77) | FDPSBLMTDP1LMNABTN3A1 | |
| SCHEMBL1533902 | 0.70 | — | — | |
| SCHEMBL14178230 | 0.67 | — | — | |
| SCHEMBL10037189 | 0.67 | — | — | |
| SCHEMBL2134670 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190546-A1 | Methods and compositions for sequencing a nucleic acid | FLUIDIGM CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190546-A1 | Methods and compositions for sequencing a nucleic acid | RNGTT, POLN, NT5C3B | FDPS 433/4885BLM 89/4885TDP1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.